Windtree Therapeutics Inc (WINT)

[JoeBlack]

Change in Directors or Principal Officers, Financial Statements a



Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of July 15, 2008, Discovery Laboratories, Inc. (the "Company") and each of Robert Segal, M.D., F.A.C.P., Senior Vice President, Medical and Scientific Affairs and Chief Medical Officer, and Charles F. Katzer, Senior Vice President, Manufacturing Operations, entered into an Amendment (collectively, the "Amendments") to their respective Amended and Restated Employment Agreements dated as of May 4, 2006 (the "Agreements"). Under each of the Amendments, the term of the Agreements is extended through December 31, 2009. The Agreements remain subject to automatic one-year extensions unless, as provided in the Agreements, at least 90 days notice of non-extension is provided by either the Company or the respective executive.

The description of the terms and conditions of the Amendments and the Agreements and the rights and obligations of the Company and executives in connection therewith are qualified by reference in their entirety to the definitive terms and conditions of the Amendments, the form of which is attached hereto as Exhibits 10.1 and 10.2, and the Agreements, filed as exhibits to the Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2006 and March 16, 2007.